Orange with Media Services, published on Thursday, November 03, 2022 at 4:34 p.m.
This Thursday, November 3, the American pharmaceutical giant Pfizer and its German partner BioNTech announced the launch of the first trial phase of a vaccine combining protection against Covid-19 and influenza.
A serum that protects both against the flu and against Covid-19. This Thursday, November 3, the American pharmaceutical giant Pfizer and its German partner BioNTech announced the launch of the first trial phase of a vaccine candidate based on messenger RNA combining protection against both viruses. The two laboratories have already developed one of the best-selling Covid vaccines in the world.
A combination vaccine using mRNA technology “could simplify vaccination practices against these two respiratory pathogens, potentially leading to a better vaccination coverage for both diseases”, said Annaliesa Anderson, chief scientific officer at Pfizer, in a statement.
Pfizer and BioNTech join other laboratories who are also trying to develop a combined vaccine: the American Moderna has started phase 1 of a vaccine against influenza and Covid, he confirmed this Thursday on the sidelines of the announcement of its quarterly results. In mid-October, the American biotechnology laboratory Novavax announced the “positive results of the phase 1 and 2″ clinical trial of a vaccine candidate of this type.
Testing the immune response of a combination vaccine candidate
By 2020, BioNTech and Pfizer had been able to quickly and successfully create the world’s first approved Covid-19 vaccine, which has generated billions of euros in revenue for both companies. The company from Mainz (West Germany) will be in charge of testing the safety, the immune response and the optimal dose level of a combined candidate vaccine, by recruiting 180 healthy volunteers aged 18 to 64 in the United States. United, according to a press release. The follow-up period for each participant will be six months.
Messenger RNA is used to command human cells to manufacture proteins present in the virus in order to to accustom the immune system to recognize it and neutralize it. The testing phase will serve to uncover “the potential of mRNA vaccines targeting more than one pathogen,” Ugur Sahin, CEO and co-founder of BioNTech, said in the statement.